ARTICLE | Finance

Philanthropy with muscle

Why CureDuchenne venture philanthropy targeting €5M for Prosensa

October 6, 2014 7:00 AM UTC

CureDuchenne Ventures' latest venture philanthropy funding project will fill a €5 million ($6.3 million) funding gap for Prosensa Holding N.V. (NASDAQ:RNA) as the biotech advances its pipeline of therapies for Duchenne muscular dystrophy. The project, dubbed Pro200, is CureDuchenne's third rescue mission for stalled DMD assets.

"Over the past three years, we've been grappling with how to institutionalize what we were doing, how to make it more impactful," CureDuchenne co-founder and President Debra Miller told BioCentury...